Department of Gastric Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
Digestion Department, Shanxi Provincial Cancer Hospital, Taiyuan, People's Republic of China.
Oncologist. 2021 May;26(5):e756-e768. doi: 10.1002/onco.13695. Epub 2021 Feb 8.
Gastric cancer (GC) has a high incidence and mortality rate, especially in East Asians, and about 90% of GCs are adenocarcinomas. Histological and etiological heterogeneity and ethnic diversity make molecular subtyping of GC complicated, thus making it difficult to determine molecular division systems and standard treatment modalities. Limited cohorts from South Korea, Singapore, Australia, and Japan have been studied; however, the mutational landscape of gastric adenocarcinomas in Chinese patients is still unknown.
We performed a targeted sequencing panel focusing on cancer-related genes and tumor-associated microorganisms of 529 gastric adenocarcinoma samples with matched blood controls. We identified 449 clinically relevant gene mutations.
Approximately 47.1% of Chinese patients with GC harbored at least one actionable mutation. The top somatic mutations were TP53, ARID1A, LRP1B, PIK3CA, ERBB2, CDH1, KRAS, FAT4, CCNE1, and KMT2D. Truncation mutations of ARID1A, KMT2D, RNF43, TGFBR2, and CIC occurred in patients with high tumor mutational burden. Gene amplifications of ERBB2, CCNE1, CDK12, and CCND1 were detected in patients with low tumor mutational burden. Pathway analysis revealed common gene alterations in the Wnt and PI3K/Akt signaling pathways. The ratio of patients with high microsatellite instability was significantly lower than other cohorts, and high microsatellite instability and Epstein-Barr virus (EBV)-positive features seemed mutually inclusive in Chinese patients with GC. In 44 (8.3%) patients, 45 germline mutations were identified, among which SPINK1 mutations, all SPINK1 c.194 + 2T > C, were present in 15.9% (7/44) of patients. Microorganisms found in Chinese patients with GC included Helicobacter pylori, EBV, hepatitis B virus, and human papillomavirus types 16 and 18.
Identification of varied molecular features by targeted next-generation sequencing provides more insight into patient stratification and offers more possibilities for both targeted therapies and immunotherapies of Chinese patients with GC.
This study investigated the genomic alteration profile of 529 Chinese patients with gastric adenocarcinoma by deep targeting sequencing, which might be the largest Chinese cohort on the genomic research of gastric adenocarcinoma up to now.
胃癌(GC)发病率和死亡率高,尤其在东亚地区,约 90%的 GC 为腺癌。组织学和病因学的异质性以及种族多样性使 GC 的分子分型变得复杂,因此难以确定分子划分系统和标准治疗方式。此前已有来自韩国、新加坡、澳大利亚和日本的有限队列进行了相关研究,但中国患者胃腺癌的突变情况仍不清楚。
我们对 529 例胃腺癌样本及其配对血样进行了癌症相关基因和肿瘤相关微生物的靶向测序面板分析,共鉴定出 449 个具有临床意义的基因突变。
约 47.1%的中国 GC 患者至少存在一种可靶向治疗的突变。最常见的体细胞突变为 TP53、ARID1A、LRP1B、PIK3CA、ERBB2、CDH1、KRAS、FAT4、CCNE1 和 KMT2D。在高肿瘤突变负荷的患者中,ARID1A、KMT2D、RNF43、TGFBR2 和 CIC 的截断突变较为常见。在低肿瘤突变负荷的患者中,发现 ERBB2、CCNE1、CDK12 和 CCND1 的基因扩增。通路分析显示 Wnt 和 PI3K/Akt 信号通路中存在常见的基因改变。高微卫星不稳定性患者的比例明显低于其他队列,且高微卫星不稳定性和 EBV 阳性特征在我国 GC 患者中似乎相互包含。在 44 例(8.3%)患者中,发现 45 种种系突变,其中 SPINK1 突变,即所有 SPINK1 c.194 + 2T > C,在 15.9%(7/44)的患者中存在。在中国 GC 患者中发现的微生物包括幽门螺杆菌、EBV、乙型肝炎病毒和人乳头瘤病毒 16 型和 18 型。
通过靶向下一代测序鉴定的各种分子特征,为患者分层提供了更深入的了解,并为中国 GC 患者的靶向治疗和免疫治疗提供了更多的可能。
本研究通过深度靶向测序,对 529 例中国胃腺癌患者的基因组改变谱进行了研究,这可能是迄今为止关于中国胃腺癌基因组研究中最大的中国队列。